B7-33

Muscle/RecoveryRelaxin-2 analog / researchEmerging

Single-chain relaxin-2 analog designed at Monash University as an RXFP1 agonist for anti-fibrotic and vasodilatory research. Preclinical; not FDA-approved.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): ~5 kDa
Half-life: Short; stabilized vs native relaxin-2
Unit: mcg
Administration Route: —
Frequency: —
Last updated: 8/23/2026
Targets: RXFP1 (relaxin family peptide receptor 1)

Overview

Single-chain relaxin-2 analog designed at Monash University as an RXFP1 agonist for anti-fibrotic and vasodilatory research. Preclinical; not FDA-approved.

Protocol

Dosage Range: Per research protocol
Frequency: —
Cycle: —
Administration Route: —
Reconstitution Guide: —

Science

Mechanism of Action

Minimized relaxin-2 analog that activates RXFP1, promoting vasodilation, extracellular-matrix remodeling, and anti-fibrotic signaling in heart and kidney models.